CTKB
vs
S&P 500
CTKB
S&P 500
Over the past 12 months, CTKB has underperformed S&P 500, delivering a return of +16% compared to S&P 500's +20% growth.
Stocks Performance
CTKB vs S&P 500
Performance Gap
CTKB vs S&P 500
Performance By Year
CTKB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cytek Biosciences Inc
Glance View
Cytek Biosciences makes instruments and software used in flow cytometry, a lab method that analyzes cells by passing them in front of lasers and detectors. Its main products are cell-analyzing instruments, reagents, and data-analysis tools that help researchers and labs measure many properties of single cells at once. The company’s systems are used in life-science research, drug development, and clinical and translational labs that need detailed cell analysis. Cytek sells mainly to academic labs, biotech and pharmaceutical companies, and clinical research organizations. It makes money by selling instruments upfront and then earning recurring revenue from reagents, service contracts, and software tied to those systems. That model gives it both one-time equipment sales and repeat business from customers who keep using the platform for ongoing experiments. What makes Cytek different is its focus on high-parameter flow cytometry, which lets scientists collect more information from each cell than many older systems. In practice, it sits between the makers of lab equipment and the researchers who need precise cell data, with its hardware, reagents, and analysis software designed to work together as a single workflow.
